En fase 1-undersøgelse af GTX-B001 hos sunde underjetter og patienter med kold urticaria (CHILL-MC)
En fase 1, randomiseret, dobbeltblind, placebokontrolleret, enkelt stigende dosis tolerabilitet, farmakokinetisk, farmakodynamisk og foreløbig effektivitetsforsøg af GTX-B001 hos raske frivillige (del A) og patienter med koldt induceret urticaria (del B)
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
GTX-B001 is a humanized bispecific antibody than binds with one arm to a protein called c-Kit and with the second arm to a protein called CD203c, both expressed on mast cells.
This study is a randomized, double-bind, placebo-controlled phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of a single dose of GTX-B001 in healthy participants (Part A) and in patients with chronic inducible urticaria (cold urticaria and symptomatic dermographism) who remain symptomatic despite treatment with antihistamines (Part B). In part B, the preliminary efficacy of GTX-B001 on the signs and symptoms of chronic inducible urticaria will also be evaluated.
48 healthy participants are estimated to be enrolled in part A in five ascending cohorts, while 24 patients with chronic inducible urticaria are estimated to be enrolled in Part B in two ascending cohorts.
Potential participants will be screened for up to 4 weeks prior to enrollment. GTX-B001 will be administered intravenously on Day 1 to randomized participants who will be followed for 12 weeks post-treatment.
Participants will be required to attend a total of 9 visits including the screening visit.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Berlin, Tyskland
- Rekruttering
- Charite Universitaetsmedizin Berlin
-
Kontakt:
- Principal Investigator
- Telefonnummer: +49 30 450 518 219
- E-mail: hautsache-ifa@charite.de
-
Berlin, Tyskland
- Aktiv, ikke rekrutterende
- Charité Research Organization gmbh
-
Halle, Tyskland
- Rekruttering
- Dermatologische Praxis
-
Kontakt:
- Principal Investigator
- Telefonnummer: +493452082056
- E-mail: info@hautarzthalle.de
-
Marburg, Tyskland
- Rekruttering
- Universitaetsklinikum Giessen und Marburg GmbH
-
Kontakt:
- Principal Investigator
- Telefonnummer: +4964215862932
- E-mail: hautklinik-marburg@uk-gm.de
-
Münster, Tyskland
- Rekruttering
- Universitatsklinikum Münster
-
Kontakt:
- Principal Investigator
- Telefonnummer: +492518355555
- E-mail: derma@ukmuenster.de
-
Tübingen, Tyskland
- Rekruttering
- Universitaetsklinikum Tübingen
-
Kontakt:
- Principal Investigator
- Telefonnummer: +4970712983471
- E-mail: studienzentrum.immundermatologie@med.uni-tuebingen.de
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key inclusion Criteria (Part A):
- The subject is between 18 and 55 years of age (both inclusive) at the date of screening.
- The subject is in good general health based on the medical history, physical examination and the results of vital signs, electrocardiogram and clinical laboratory, as judged by the investigator.
Key inclusion Criteria (Part B):
- The subject is between 18 and 75 years of age (both inclusive) at the date of screening
- A history of signs and/or symptoms of ColdU or SD experienced ≥ 3 months prior to screening.
- For ColdU patients, a positive provocation test during screening and baseline, using the TempTest® device.
- For SD patients, a positive provocation test with at least 3 pins during screening and baseline, using the FricTest® device.
- Inadequate control of ColdU or SD by second generation H1-antihistamine (sgAH) as defined as the presence of itch and hives following a trigger (e.g. cold or scratching, respectively) within the last 6 weeks prior to screening in spite of use of a sgAH.
- A Urticaria Control Test (UCT) score of < 12 at screening.
Key exclusion Criteria (Parts A & B):
- Presence of any clinically significant illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, or endocrine disease or disorder that would interfere with the patient's safety or the interpretation of trial results in the judgment of the investigator.
- Treatment with an investigational drug or intervention for any condition within three months of screening, or concurrent participation in another clinical trial in which an investigational drug is administered.
- Treatment with immunomodulating therapy (e.g., intravenous or intramuscular immunoglobulins, systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus, mycophenolate mofetil, hydroxychloroquine, infliximab, adalimumab, etanercept, etc.) within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.
- Use of any monoclonal antibody or therapeutic protein within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.
- History of anaphylaxis, autoimmune disorders requiring more than topical medication, or asthma requiring regular use of inhaled medication within the past 5 years, unless, in the opinion of the Investigator, the condition is not considered clinically significant and is unlikely to affect subject safety or study outcomes.
Additionally for Part B:
- Disease with symptoms of urticaria or angioedema other than Chronic Urticaria (CU), for example urticaria vasculitis, erythema multiforme, mastocytosis, or drug-induced urticaria. Patients with concomitant Chronic Spontaneous Urticaria (CSU) or other forms of Chronic Inducible Urticaria (CIndU) are eligible provided that symptoms at screening are consistent with ColdU or SD and that ColdU or SD is the dominant form of CU.
- Any other skin disease associated with chronic itching that might influence in the investigators' opinion of the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or psoriasis.
- Receipt of any biologic therapy for urticaria control (e.g. omalizumab, dupilumab, ligelizumab, etc.) within three months of screening (whether on-label or off-label).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part A (HV) - GTX-B001
Healthy participants will receive a single dose of GTX-B001 |
Single infusion of one of up to five dosages of GTX-B001
Andre navne:
|
|
Placebo komparator: Part A (HV) - Normal Saline
Healthy participants assigned to receive placebo will receive a single dose of normal saline |
Single infusion of normal saline |
|
Eksperimentel: Part B (ColdU/SD) - GTX-B001
Patients with cold urticaria or symptomatic dermographism will receive a single dose of GTX-B001 |
Single infusion of one of up to five dosages of GTX-B001
Andre navne:
|
|
Placebo komparator: Part B (ColdU/SD) - Normal Saline
Patients with cold urticaria or symptomatic dermographism assigned to receive placebo will receive a single dose of normal saline |
Single infusion of normal saline |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety as assessed by the incidence and severity of adverse events (Parts A and B)
Tidsramme: Day 1 to Day 85
|
Safety and tolerability of a single intravenous infusion of GTX-B001 as assessed by the percentage of subjects at each dose level with Grade 2 or higher adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE). |
Day 1 to Day 85
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
GTX-B001 pharmacokinetics (Parts A and B)
Tidsramme: Day 1 to Day 85
|
Serum concentrations of GTX-B001 at specified visits |
Day 1 to Day 85
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
GTX-B001 pharmacodynamics (Parts A and B)
Tidsramme: Day 1 to Day 85
|
Change from baseline in blood biomarkers such as serum tryptase |
Day 1 to Day 85
|
|
GTX-B001 pharmacodynamics in skin (Part B)
Tidsramme: Day 1 to Day 29
|
Change from baseline in mast cell density and mast cell activation markers upon cold or friction provocation, assessed from skin punch biopsy at baseline and three times post-treatment. |
Day 1 to Day 29
|
|
Evaluation of immunogenicity (Parts A and B)
Tidsramme: Day 1 to Day 85
|
Incidence of anti-drug antibodies |
Day 1 to Day 85
|
|
Disease control (Part B ColdU) - Critical Temperature Threshold (CTT)
Tidsramme: Day 1 to Day 85
|
Change from baseline and percentage of responders in Critical Temperature Threshold (CTT) over time as determined by provocation testing using the TempTest®. The CTT determines the highest temperature that induces symptoms. |
Day 1 to Day 85
|
|
Disease control (Part B SD) - Critical Friction Threshold (CFT)
Tidsramme: Day 1 to Day 85
|
Change from baseline and percentage of responders in Critical Friction Threshold (CFT) over time as determined by provocation testing using the FricTest®. The CFT determines the shortest pin length (or lowest pressure) that induces symptoms. |
Day 1 to Day 85
|
|
Disease control (Part B) - Urticaria Control Test (UCT)
Tidsramme: Day 1 to Day 85
|
Change from baseline and percentage of responders for the Urticaria Control Test (UCT). Total score ranges from 0 to 16. A score of 12 or higher indicates well-controlled chronic urticaria, while a score below 12 suggests poorly controlled disease. |
Day 1 to Day 85
|
|
Disease control (Part B ColdU) - Cold Urticaria Activity Score (Cold UAS)
Tidsramme: Day 1 to Day 85
|
Change from baseline in Cold Urticaria Activity Score (Cold UAS). The total score ranges from 0 to 6, the higher the score the higher the disease activity. |
Day 1 to Day 85
|
|
Disease control (Part B SD) - Symptomatic Dermographism Activity Score (SDAS)
Tidsramme: Day 1 to Day 85
|
Change from baseline in Symptomatic Dermographism Activity Score (SDAS) |
Day 1 to Day 85
|
|
Disease control (Part B ColdU) - Cold Urticaria Quality of Life Questionnaire (ColdU-QoL)
Tidsramme: Day 1 to Day 85
|
Change from baseline in Cold Urticaria Quality of Life Questionnaire (ColdU-QoL). The total score ranges from 0 to 100, the higher the score the higher the impairment. |
Day 1 to Day 85
|
|
Disease control (Part B SD) - Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL)
Tidsramme: Day 1 to Day 85
|
Change from baseline in Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL). The total score ranges from 0 to 100, the higher the score the higher the impairment. |
Day 1 to Day 85
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Kronisk nældefeber
- Patologiske processer
- Kronisk sygdom
- Sygdomsegenskaber
- Sygdomme i immunsystemet
- Overfølsomhed, Øjeblikkelig
- Overfølsomhed
- Hudsygdomme, vaskulære
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Kronisk inducerbar nældefeber
- Kold Nældefeber
- Hudsygdomme
- Nældefeber
- Familiel dermografisme
- Farmaceutiske præparater
- Krystalloidopløsninger
- Isotoniske løsninger
- Løsninger
- Salinopløsning
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GRN-GTXB001-001
- 2025-522126-13-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .